Human organoids reveal how to reverse “irreversible” nerve damage
Journal: Cell Reports
Author: Gibbons G, Fuchsberger T, Abdelgawad M et al., UK
Researchers developed a human corticospinal organoid-spinal connectoid model that reveals how neuronal maturation restricts axon regeneration and demonstrates that targeting maturation-associated transcriptional programs with repurposable drugs can restore post-injury axon regrowth, opening new avenues for CNS repair and regenerative medicine
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Journal: New England Journal of Medicine
Author: Eileen M et al.,
A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn’t be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.
Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding
Journal: Nature
Author: Zeng, J., Cheng, Z., Chen, H. et al., USA
Researchers engineered an RNA-guided CRISPR-Cas12a2 system that selectively recognizes cancer-specific mutations and triggers chromatin shredding, inducing DNA damage and cell death in tumor cells, offering a promising precision-medicine strategy for targeting previously undruggable cancer drivers such as mutant p53
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration
Journal: Cancer
Author: Zhu L, Zhang S, Li B et al., China
Researchers identified STK40 as a key driver of immune evasion in hepatocellular carcinoma, showing that its inhibition restores tumor sensitivity to immune attack, enhances T cell activation, and significantly improves responses to PD-1 blockade, positioning STK40 as a promising target for overcoming immunotherapy resistance
